Skip to main content
NewslettersWatchlist

Nextcure Inc(NXTC-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.6500
Day High1.7600
Open:1.7000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor
Globe Newswire
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
Globe Newswire
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium
Globe Newswire
NextCure to Present at the JMP Securities Life Sciences Conference
Business Wire
Chau Khuong Joins Catalio Capital Management as General Partner
Globe Newswire
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
Globe Newswire
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Globe Newswire
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
Globe Newswire
NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting
Globe NewsWire
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Globe NewsWire
NextCure Reports Second Quarter 2021 Financial Results
Globe NewsWire
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
Globe NewsWire
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
Globe NewsWire
NextCure to Present at the JMP Securities Life Sciences Conference
Globe NewsWire
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Globe NewsWire
NextCure Reports First Quarter 2021 Financial Results
Globe NewsWire
NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference
Globe NewsWire
NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit
Globe NewsWire
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
Globe NewsWire
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
Globe NewsWire
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Globe NewsWire
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
Globe NewsWire
NextCure to Host Virtual R&D Update Event on March 4, 2021
Business Wire
LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
Globe NewsWire
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
Business Wire
LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
Globe NewsWire
NextCure Provides Updates on NC318 Clinical Program
Globe NewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC
Globe NewsWire
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference

Profile

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.